# GLP-1 and Cardiovascular Health: The SELECT Trial and Beyond Source: https://www.dietglp.com/blog/glp1-and-cardiovascular/ Published: 2026-04-16 Keywords: glp-1 cardiovascular, select trial semaglutide, ozempic heart, wegovy cardiovascular benefit **TL;DR:** The SELECT trial showed semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in non-diabetic patients with obesity and prior cardiovascular disease. Cardiovascular benefit appears partly independent of weight loss. Many cardiologists now prescribe GLP-1 for high-risk patients regardless of diabetes status. The SELECT trial, published in 2023, was a turning point. It showed that semaglutide didn't just help patients lose weight — it reduced major cardiovascular events in non-diabetic patients with obesity and prior cardiovascular disease. This shifted GLP-1 prescribing from weight management toward cardiovascular medicine. ## What SELECT showed The Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) trial: - 17,604 patients, age 45+, with BMI ≥27 and prior cardiovascular disease, no diabetes - Randomized to semaglutide 2.4 mg/week or placebo - Followed ~3 years **Primary endpoint** (major adverse cardiovascular events — heart attack, stroke, or cardiovascular death): - Semaglutide: 6.5% - Placebo: 8.0% - **20% relative risk reduction** (highly statistically significant) The benefit appeared independent of weight loss — patients who lost less weight also had cardiovascular benefit, suggesting GLP-1 has direct cardiovascular effects beyond just weight reduction. ## What this changed in clinical practice Before SELECT, GLP-1 was framed as a weight loss / diabetes drug. After SELECT: - Many cardiologists now consider GLP-1 for high-risk obese patients regardless of diabetes - Medicare expanded Wegovy coverage specifically for cardiovascular event reduction in patients with established CVD (a 2024 expansion) - Some treatment guidelines now place GLP-1 alongside statins as evidence-based cardiovascular medications for the right patient - The "weight loss" framing has shifted toward "metabolic and cardiovascular intervention" ## How GLP-1 helps the heart Multiple mechanisms: **1. Weight loss.** Reduces blood pressure, improves lipids, reduces visceral fat — all cardiovascular benefits. **2. Blood sugar improvement.** Better glycemic control reduces atherosclerosis progression. **3. Anti-inflammatory effects.** GLP-1 has direct anti-inflammatory effects on blood vessels. **4. Reduced visceral fat specifically.** Visceral fat is the most cardiometabolically dangerous; GLP-1 preferentially reduces it. **5. Direct cardiovascular receptor effects.** GLP-1 receptors are in the heart and blood vessels themselves. **6. Improved lipid profile.** Reduced triglycerides, modest LDL reduction, often improved HDL. **7. Blood pressure reduction.** Average ~5 mmHg reduction in systolic BP. ## Other cardiovascular trials SELECT is the headline, but the cardiovascular GLP-1 evidence base is broad: - **LEADER** (liraglutide in diabetics): 13% reduction in major CV events - **SUSTAIN-6** (semaglutide in diabetics): 26% reduction in major CV events - **REWIND** (dulaglutide in diabetics): 12% reduction in major CV events - **HARMONY** (albiglutide): 22% reduction - **PIONEER 6** (oral semaglutide): trend toward CV benefit, not significant - **SURPASS-CVOT** (tirzepatide): ongoing — results expected to show cardiovascular benefit The pattern is consistent: GLP-1 medications generally produce ~10–25% reductions in cardiovascular events. ## Who benefits most The cardiovascular benefit appears strongest in patients with: - Established cardiovascular disease (prior heart attack, stroke, peripheral arterial disease) - Multiple risk factors (diabetes + hypertension + obesity) - High-risk lipid profiles - Chronic kidney disease (which is itself a CV risk amplifier) Patients without established CV disease and without significant risk factors derive less absolute benefit, though the relative benefit is similar. ## Combining with other CV medications GLP-1 is generally safely combined with: - Statins - Blood pressure medications - Aspirin - Other diabetes medications (with insulin/sulfonylurea dose adjustments) The combinations often produce additive benefit. A patient on a statin, ACE inhibitor, and GLP-1 has substantially better cardiovascular outcomes than any one alone. ## What about heart failure? GLP-1 effects in heart failure are still being characterized: - **STEP-HFpEF** (semaglutide in heart failure with preserved ejection fraction): Significant symptom and biomarker improvements - Reduced concerns about earlier heart failure signals (no longer considered a risk in current data) - Generally considered safe in stable heart failure - Acute heart failure: caution; not first-line Talk to your cardiologist if you have any heart failure history. ## The kidney connection Kidney function intersects significantly: - **FLOW** trial (semaglutide in CKD with diabetes): Reduced kidney disease progression - GLP-1 generally protective for kidney function in obese / diabetic patients - Acute kidney injury risk in patients with severe nausea/vomiting and dehydration — staying hydrated matters ## What this means for patients If you have cardiovascular disease + obesity (with or without diabetes), GLP-1 is increasingly considered a standard-of-care option. Discuss with your cardiologist or PCP. If you're considering GLP-1 primarily for cardiovascular reasons, useful framing for the conversation: - "I have obesity + prior CV event — does the SELECT data apply to me?" - "Could Wegovy be part of my cardiovascular prevention plan?" - "Would my insurance cover it under the cardiovascular indication now?" ## Bottom line GLP-1 medications reduce major cardiovascular events by ~10–25% across multiple large trials. SELECT specifically showed 20% reduction in non-diabetic obese patients with prior CV disease. The benefit appears partly independent of weight loss. Patients with established cardiovascular disease + obesity should discuss GLP-1 with their cardiologist; the framing has shifted from "weight loss drug" to "evidence-based cardiovascular medication for the right patient."